CD163 and cancer: However, Kaplan–Meier survival estimates of four combinations of low/high number of communicating CD163+ TAMs and low/high median cancer-to-CD163+ NND (Figure 4A) suggested possibly more than 2 different risk categories based on the dichotomized number of communicating CD163+ TAMs and the median cancer-to-CD163+ NND.